Prostate Cancer Clinical Trial
Evaluation of the Added Value of PSMA-PET Compared With Multi-parametric MRI in the Detection and Classification of Prostate Lesions
|Source||Assuta Medical Center|
|Contact||David Groshar, MD|
|Status||Not yet recruiting|
|Start date||June 1, 2017|
|Completion date||June 1, 2019|
Prostate cancer is a common disease in men. In prostate 35% of biopsies, usually done due to
increased PSA levels or clinical suspicion, are false negative, despite malignancy.
Multi-parametric prostate MRI detects malignant neoplasm lesions better than other imaging devices.
A sonar-guided prostate biopsy based on multi-parametric MRI images improves detection of malignancy. Ga68 PSMA-PET test uses a radioactive marker that binds to the prostate's cells and is shown to be a primary prostate tumor site in addition to metastasis.
We believe that the combination of measures from a single Ga68 PSMA and multi-parametric MRI test can lead to further improvement in malignancy, better biopsy guidance, and optimal treatment for the patient.
Prostate cancer is the most common and second leading cause of cancer death in men.
Mostly, patients undergo prostate biopsy whenever abnormal digital rectal examination or elevated prostate specific antigen (PSA) levels have been found. Traditionally, trans-rectal US (TRUS) biopsy is performed using 10-12 needles that are inserted into different areas of the prostate gland. Despite this, up to 35% of prostate cancers are still not diagnosed.
The use of multi-parametric prostate MRI (mnMRI) in which T2-weighted sequence, diffusion weighted imaging (DWI) and dynamic contrast enhanced-imaging (DCE) are used has shown to increase the cancer detection rate of clinically significant lesions and better stratify prostate cancer compared to other modalities(3). A pre-biopsy mnMR can identify suspicious lesions that can be targeted on biopsy. Indeed, the use of MRI- US fusion in which pre-biopsy MR images are incorporated with real time biopsy US images has shown to reduce the number of biopsies performed on patients with low grade cancer and increase the detection of intermediate-high risk subgroups of patients(4).
The introduction of PET/MR with the use of PSMA as a radiotracer offers the potential to add a new biomarker to the well-established mnMRI. Different PSMA metrics such as SUV, metabolic tumor volume (MTV) and kinetic parameters can be correlated with lesion detection rate and Gleason score and help tailoring the precise treatment to patients.
The purpose of the current study is to reveal if PSMA-PET has an added value in the detection and stratification of prostate cancer to the currently used nmMRI.
First Objective: To examine whether PSMA-PET increases detection sensitivity and allows better classification of prostate lesions.
Secondary objective: To check the correlation between PSMA-PET measurements and the various indices of multi-parametrial MRI and the histological results.
The work hypothesis: The PSMA PET MRI measurements will improve the ability to identify and classify prostate lesions and conform to the various MRI measurements Research Methods-
The study population:
Patients who have a clinical suspicion of prostate cancer that will be referred to the prostate multi-parameter MRI before deciding on a prostate biopsy Sampling Method: The study is prospective and will include subjects who meet the criteria for inclusion in a continuous manner. The subjects will undergo a PET MRI PSMA test, followed by a prostate fusion biopsy (up to two weeks after the test) using US fusion technology.
Parameters of the PSMA PET-MR test :
PET Measurements: Quantitative calculation of the absorption of suspicious lesions.
The type of biopsy will depend on the PET MRI results. If a suspicious finding is found according to the PET or MR test or both, the biopsy will be done using the US FUSION MRI, and if a suspicious lesion is not seen, the biopsy will be performed by sonar alone, or not at all.
Sample size: 70 participants.
|Recruiting||NCT03177759 - Living With Prostate Cancer (LPC)||N/A|
|Completed||NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data||N/A|
|Not yet recruiting||NCT03160365 - Innovative Planning and Guidance System for Prostate Focal Brachytherapy||N/A|
|Active, not recruiting||NCT02124668 - A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy||Phase 2|
|Completed||NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis||N/A|
|Active, not recruiting||NCT00779168 - White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy||Phase 1|
|Recruiting||NCT01990196 - Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer||Phase 2|
|Recruiting||NCT02766543 - Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer||Phase 2|
|Not yet recruiting||NCT03157947 - Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer||N/A|
|Recruiting||NCT02906241 - PACCT: Partnering Around Cancer Clinical Trials||N/A|
|Recruiting||NCT02918357 - Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence||Phase 2/Phase 3|
|Recruiting||NCT02766686 - Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons||N/A|
|Recruiting||NCT02886598 - Safety and Efficacy of Firmagon® (Degarelix) for Injection||N/A|
|Recruiting||NCT02747342 - A Phase 1 Trial of SHR3680 in Prostate Cancer as Monotherapy||Phase 1|
|Recruiting||NCT02919111 - Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients||Phase 2/Phase 3|
|Recruiting||NCT02543255 - Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)||Phase 2|
|Recruiting||NCT02911922 - Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer||N/A|
|Recruiting||NCT02916537 - A Phase 1 Trial for Safety and Imaging Evaluation of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA)||Phase 1|
|Recruiting||NCT02917161 - Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study||N/A|
|Enrolling by invitation||NCT02840552 - The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer||Phase 3|